GR Defect in Sputum Cells in COPD

This study has been completed.

First Received: September 8, 2005 Last Updated: August 12, 2008 History of Changes

Sponsors and Collaborators:	Imperial College London AstraZeneca
Information provided by:	Imperial College London
ClinicalTrials.gov Identifier:	NCT00159276

Purpose

To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

Condition	Intervention
Chronic Obstructive Pulmonary Disease (COPD)	Procedure: Induced Sputum

MedlinePlus related topics: COPD (Chronic Obstructive Pulmonary Disease)

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	GR Defect in Sputum Cells in COPD

Further study details as provided by Imperial College London:

Estimated Enrollment:	30
Study Start Date:	December 2005
Estimated Study Completion Date:	December 2008

Eligibility

Ages Eligible for Study:	35 Years to 85 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Patients with moderate (stage II, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers.
Written informed consent

Exclusion Criteria:

Current upper respiratory tract infections
Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159276

Locations

United Kingdom
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY

Sponsors and Collaborators

Imperial College London

AstraZeneca

Investigators

Principal Investigator:

Sergei A Kharitonov, MD PhD

Imperial College London

More Information

No publications provided

Study ID Numbers:	D5899N00007A
Study First Received:	September 8, 2005
Last Updated:	August 12, 2008
ClinicalTrials.gov Identifier:	NCT00159276 History of Changes
Health Authority:	United Kingdom: Research Ethics Committee

Study placed in the following topic categories:

Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:

Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases
Pulmonary Disease, Chronic Obstructive

ClinicalTrials.gov processed this record on May 06, 2009